New FOA: Integrating Biospecimen Science Approaches
into Clinical Assay Development (U01)
This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development due to biopsy biospecimen preanalytical variability. A pre-application Webinar will be held on Friday,
May 6, 2016. Webinar details.
The 2016 version of the
NCI Best Practices for Biospecimen Resource
This foundational document for biobanking has been updated and revised to provide more current and detailed recommendations related to biospecimen and data quality.
Welcome to the Cancer Diagnosis Program!
The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.
For more information about the Cancer Diagnosis Program and its Branches, please click here.